Alloimmunization

doi:10.1017/9781108975780.012

Chapter 10 - Alloimmunization

from Section 1 - Obstetric Aspects of Antenatal Care

Published online by Cambridge University Press: 23 February 2023

Noor Amily ,

Amira El-Messidi and

Karen Fung-Kee-Fung

Edited by

Amira El-Messidi and

Alan D. Cameron

Show author details

Amira El-Messidi: Affiliation:
McGill University, Montréal
Alan D. Cameron: Affiliation:
University of Glasgow

Book contents

Get access

Summary

A new patient presents for consultation and transfer of care to your high-risk obstetrics unit at a tertiary center. She is a 34-year-old G4P2A1L2 at 14+3 weeks’ gestation with anti-c antibodies detected on routine testing; results have been confirmed at your hospital’s laboratory. All other prenatal investigations are unremarkable, including first-trimester sonogram and aneuploidy risk assessment.

Keywords

Red cell antibodies, alloimmunization Risk factors Fetal antigen status Maternal-fetal surveillance Fetal middle cerebral artery Doppler technique Fetoplacental sonographic pathology Fetal anemia, definitions Packed red blood cell transfused volume Delivery timing Mode of delivery Intrauterine transfusion, purpose, techniques, complications Donor packed red blood cells, characteristics Delivery management Postpartum counseling Fetal hemolytic disease, prophylactic interventions

Type: Chapter
Information: OSCEs in Obstetrics and Maternal-Fetal Medicine
An Evidence-Based Approach
, pp. 127 - 140

DOI: https://doi.org/10.1017/9781108975780.012 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Readings

Brennand, J, Cameron, A. Fetal anaemia: diagnosis and management. Best Pract Res Clin Obstet Gynaecol. 2008;22(1):15–29.Google Scholar

Castleman, JS, Kilby, MD. Red cell alloimmunization: a 2020 update. Prenat Diagn. 2020;40(9):1099–1108.CrossRef Google Scholar PubMed

The management of women with red cell antibodies during pregnancy. Green Top Guideline number 65, 2014. Available at www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg65. Accessed February 22, 2021.Google Scholar

Koelewijn, JM, Vrijkotte, TG, de Haas, M, et al. Risk factors for the presence of non-rhesus D red blood cell antibodies in pregnancy. BJOG. 2009;116(5):655–664.Google Scholar

Moise, KJ Jr, Argoti, PS. Management and prevention of red cell alloimmunization in pregnancy: a systematic review. Obstet Gynecol. 2012;120(5):1132–1139.CrossRef Google Scholar PubMed

Scottish National Clinical Guidance: Pregnant women with red cell antibodies, version 2, July 2013. Available at https://nhsnss.org/services/blood-tissues-and-cells/clinical-services/information-and-manuals-for-clinicians/. Accessed February 22, 2021.Google Scholar

Society for Maternal-Fetal Medicine, Mari, G, Norton, ME, et al. Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline No. 8: the fetus at risk for anemia – diagnosis and management. Am J Obstet Gynecol. 2015;212(6):697–710.CrossRef Google Scholar

Webb, J, Delaney, M. Red blood cell alloimmunization in the pregnant patient. Transfus Med Rev. 2018;32(4):213–219.Google Scholar

White, J, Qureshi, H, Massey, E, et al. Guideline for blood grouping and red cell antibody testing in pregnancy. Transfus Med. 2016;26(4):246–263.CrossRef Google Scholar PubMed

Zwiers, C, van Kamp, IL, Oepkes, D. Management of red cell alloimmunization. Chapter 10 in: Kilby, MD, Johnson, A, Oepkes, D, eds., Fetal Therapy: Scientific Basis and Critical Appraisal of Clinical Benefits, 2nd ed. Cambridge: Cambridge University Press; 2020.Google Scholar